We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Tel4.3
Telmisartan Research
Too few graded studies
55 peer-reviewed studies
What the evidence says
Too few graded studies
Telmisartan doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2008–2026 with a typical study size of 20,332 participants.
Based on 55 studies · 12 meta-analyses · 38 RCTs · 77,552 total participants
Confidence
High confidence
By outcome
Heart, blood pressure & strokeONTARGET showed telmisartan non-inferior to ramipril for cardiovascular death, MI, stroke, and HF hospitalization in high-risk patients · Months to years
Too few graded studies34 studies
Safety profile
Too few graded studies9 studies
Glucose, insulin & metabolicVia partial PPARγ agonism, improves insulin resistance and glucose more than other ARBs (a surrogate-marker effect) · Weeks to months
Too few graded studies7 studies
Kidney & renal health
Too few graded studies4 studies
Cholesterol & lipidsONTARGET showed telmisartan non-inferior to ramipril for cardiovascular death, MI, stroke, and HF hospitalization in high-risk patients · Months to years
Too few graded studies3 studies
Aging & healthspan (emerging)
Too few graded studies1 study
Active research area
34 studies in the last 5 years · Latest meta-analysis: 2026
200820172026
1Meta-Analysis2025
In plain English: The available RCT evidence suggests little to no difference between renin inhibitors and ARBs in terms of mortality, SAE, WDAE, adverse events, and blood pressure in people with mild primary hypertension.
Wang GM, Li LJ, Fan L, Xu M, Tang WL, Wright JM. · The Cochrane database of systematic reviews (2025)
We reported dichotomous outcomes as a risk ratio (RR) with a 95% confidence interval (CI) and continuous variables as mean difference (MD) with a 95% CI.
There may be little to no difference between renin inhibitors and ARBs in all-cause mortality (RR 0.35, 95% CI 0.07 to 1.64; 3 studies, 1932 participants; low-certainty evidence).
Authors' conclusions The available RCT evidence suggests little to no difference between renin inhibitors and ARBs in terms of mortality, SAE, WDAE, adverse events, and blood pressure in people with mild primary hypertension.
In plain English: The most common adverse event leading to discontinuation was an increase of 20% or more in the serum creatinine level.
Trident Research Group et al. · The New England journal of medicine (2026)
At a median follow-up of 2.5 years, recurrent stroke had occurred in 38 patients (4.6%) in the triple-pill group and 62 (7.4%) in the placebo group (hazard ratio, 0.61; 95% confidence interval [CI], 0.41 to 0.92; P = 0.02).
The incidence of major cardiovascular events was lower with the triple pill than with placebo (6.6% vs. 9.8%; P = 0.04).
Serious adverse events occurred in 23.2% of the patients in the triple-pill group and 26.0% of those in the placebo group.
In plain English: Low-dose GMRx2 provides superior BP reduction and a well-tolerated safety profile in patients with mild to moderate hypertension.
Shubietah A, Elgendy MS, Emara A, Abdul-Hafez HA, Awashra A, Elbably I, Abuelazm M, Mhanna M. · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2026)
Random-effects model to pool mean difference (MD) for continuous outcomes and risk ratios (RR) for binary outcomes with 95% confidence intervals (CI).
Compared with control, low-dose GMRx2 significantly reduced office systolic BP at 4-6 weeks (MD -8.84 mmHg, 95% CI [-11.27; -6.46]) and 12 weeks (MD -5.52 mmHg, 95% CI [-6.85; -4.18]).
It also increased the proportion of patients achieving target office BP at 4-6 weeks (66.7% vs. 50.2%, RR 1.20, 95% CI [1.08-1.43]) and 8-12 weeks (75.6% vs. 59.5%, RR 1.15, 95% CI [1.05-1.26]).
In plain English: Current evidence highlights ongoing uncertainty regarding the efficacy of medical therapies in reducing subthreshold AAA growth rates, rates of referral for surgical repair, or overall mortality.
Lu PYJ et al. · Interdisciplinary cardiovascular and thoracic surgery (2026)
However, propranolol (OR = 3.14, 95% CI, 1.34-7.35) and ticagrelor (OR = 5.10, 95% CI, 1.12-23.18) were associated with a higher rate of discontinuation due to adverse events.
Current evidence highlights ongoing uncertainty regarding the efficacy of medical therapies in reducing subthreshold AAA growth rates, rates of referral for surgical repair, or overall mortality.
The absence of statistically significant benefit may reflect underpowered datasets rather than definitive treatment inefficacy.
In plain English: The certainty of evidence was low for migraine days, moderate for responder rates and high for headache days, with heterogeneity between studies categorized as 'might not be important' and no serious risk of bias.DiscussionThe systematic review and meta-analysis provide robust evidence on the effect of ARBs, particularly candesartan, in prevention of episodic migraine, supporting the rationale for reconsidering its position in international guidelines.Trial RegistrationProspero CRD42023405372.
Riise HS et al. · Cephalalgia : an international journal of headache (2026)
All four studies reported the outcomes migraine days and responder (≥50% reduction of migraine days) rates, and three reported headache days.
The combined effect size for migraine days and headache days were reductions of -1.00 (95% CI: -1.51 to -0.49, p<0.001), and -1.21 (95% CI: -1.62 to -0.81, p<0.001) days per month from baseline respectively.
The odds ratio for being a responder was 2.68 (95% CI: 1.91 to 3.78, p<0.001).
In plain English: Telmisartan was non-inferior to ramipril for major cardiovascular events, but the combination of the two increased adverse events without added benefit.
ONTARGET Investigators, Yusuf, Teo, Pogue, Dyal, Copland · The New England journal of medicine (2008)
ONTARGET randomized 25,620 high-vascular-risk patients to ramipril, telmisartan, or both
Telmisartan was non-inferior (not superior) to the ACE inhibitor ramipril for the composite of CV death, MI, stroke, or HF hospitalization
Counter-evidence: the combination arm caused more hypotension, syncope, and renal dysfunction without added benefit